A Phase 3 interventional study of Cabotegravir Tablets and Cabotegravir Injectable Suspension (CAB LA) in HIV Infections, sponsored by ViiV Healthcare. Completed at 117 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 7th largest by enrollment, is one of 6 that started in 2020, is one of 12 in phase 3, and was the 22nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 687 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 14th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2020, is one of 65 in phase 3, and was the 216th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies.
Non- defined as:
Pre-menopausal females with one of the following:
The following are limited exceptions:
A change in formulation from multiple class regimens to single treatment regimens (of the same medications) would not be considered a change in ART regimen.
Exclusion Criteria:
All participants will be screened for syphilis.
Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV deoxyribonucleic acid (DNA) as follows:
Participants with HCV co-infection will be allowed entry into this study if:
i. Fib-4 score >3.25 is exclusionary ii. Fib-4 scores 1.45-3.25 requires Medical Monitor consultation Fibrosis 4 Score Formula: d. Age x (AST)/ x (square [Alanine aminotransferase {ALT}]).
Treatment with any of the following agents within 28 days of Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).
Drug: BIKTARVY Tablets (BIK)
Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase
Drug: Cabotegravir Tablets · Drug: Rilpivirine Tablets
Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.
Drug: Cabotegravir Injectable Suspension (CAB LA) · Drug: Rilpivirine Injectable Suspension (RPV LA)
Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.
Drug: Cabotegravir Injectable Suspension (CAB LA) · Drug: Rilpivirine Injectable Suspension (RPV LA)
CAB tablets were available as film coated tablets for oral administration.
CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
RPV was administered as tablets for oral administration.
RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 12/11
Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 12/11
Percentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 12/11
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 12/11
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 6/5
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 6/5
Number of Participants With Protocol-defined Confirmed Virologic Failure (CVF) Through Month 6/5 and 12/11
Protocol-defined confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>= 200 c/mL (Day 1 values are not applicable) after prior suppression to \<200 c/mL. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at Month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Cumulative number of participants with protocol defined CVF through Month 6/5 and 12/11 has been presented.
Time frame: Up to month 12
Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/5
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 6 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
Time frame: At month 6/5
Absolute Values of HIV Viral Load
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in HIV Viral Load
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Logarithm to base 10 values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Absolute Values of Cluster of Differentiation 4 Plus (CD4+) Cell Count
Blood samples were collected and CD4+ cell count was assessed using flow cytometry. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in CD4+ Cell Count
Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 12/11
Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.
Time frame: Up to Month 12/11
Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 6/5
Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.
Time frame: Up to Month 6/5
Number of Participants With Treatment-emergent Genotypic Resistance Through Month 12/11
Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.
Time frame: Up to Month 12/11
Number of Participants With Treatment-emergent Genotypic Resistance Through Month 6/5
Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.
Time frame: Up to Month 6/5
Change From Baseline in Bone Biomarkers: Specific Alkaline Phosphatase, Procollagen Type 1 N-Terminal Propeptide, Type 1 Collagen Cross-linked C-telopeptide, Osteocalcin (Micrograms Per Liter (ug/L))
Serum samples were collected to evaluate bone specific biomarkers: specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Bone Biomarkers: Serum 25-hydroxyvitamin D (Nanomoles Per Liter (Nmol/L))
Serum samples were collected to evaluate bone specific biomarkers: serum 25-hydroxyvitamin D. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Renal Biomarkers: Specific Serum Beta-2 Microglobulin, Cystatin c, Retinol Binding Protein, Urine Beta-2 Microglobulin (Milligrams Per Liter [mg/L])
Serum samples were collected to evaluate renal specific biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Renal Biomarkers: Urine Phosphate (Millimoles Per Liter (mmol/L))
Serum samples were collected to evaluate renal specific biomarkers: urine phosphate. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein 4 (Microgram Per Liter (ug/L))
Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein 4. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein/Creatinine (Milligram Per Mole (mg/Mol))
Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein/creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Renal Biomarker: Urine Beta-2 Microglobulin/ Creatinine (Grams Per Mole (g/Mol))
Serum samples were collected to evaluate renal specific biomarkers: urine beta-2 microglobulin/ creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 12/11
Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and at Month 12/11
Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 6/5
Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit.
Time frame: Baseline (Day 1) and at month 6/5
Change From Baseline in Homeostasis Model of Assessment-insulin Resistance (HOMA-IR)
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. HOMA-IR is calculated as fasting insulin microunits per liter (microU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. Higher HOMA-IR values indicate increased insulin resistance; values \<2 is generally regarded as normal. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Percentage of Participants With Treatment Preference as Assessed Using Preference Questionnaire at Month 12/11 - Q2M
Participants who had switched from the daily oral BIK regimen to CAB + RPV, were assessed as per the preference questionnaire every two months. There were 3 preference questions included to assess the preferred treatment 1) Long-acting injectable HIV medication, 2) Daily oral HIV medication, 3) No Preference. This endpoint was only planned to be analyzed for Q2M arm only. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Data represented included maintenance withdrawal or Month 12/11.
Time frame: Up to month 12/11
Change From Baseline in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)
The HIVTSQs total treatment satisfaction score comprised of 11 items based on HIVTSQ questionnaire each graded on a scale of 0 (very dissatisfied) to 6 (very satisfied) which were summed to produce a total score range of 0-66. Higher scores represent greater treatment satisfaction. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
Change From Baseline in Individual Item Scores Using HIVTSQs
The individual item scores on HIVTSQs scale were rated on a scale of 6 (very satisfied, convenient, flexible, etc.) to -6 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: Baseline (Day 1) and up to Month 12
HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/11
HIV treatment satisfaction change questionnaire (HIVTSQc) total Score is computed with items 1-11 which were summed to produce a total score range of -33 to 33. Higher score indicated greater improvement in the satisfaction with the treatment and lower score indicated greater deterioration in treatment satisfaction. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: At Month 12/11
Individual Item Scores of HIVTSQc at Month 12/11
Individual item scores were rated on a scale of +3 (much more satisfied', 'much more convenient', 'much more flexible') to -3 (much less satisfied', 'much less convenient', 'much less flexible'). Higher score indicates greater improvement, and lower score indicates greater deterioration in satisfaction with each aspect of treatment. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: At Month 12/11
Change From Month 2/1 in Dimension Scores Using Perception of Injection (PIN) Questionnaire - Q2M
The PIN questionnaire was used to explore the dimension scores based on 4 dimensions including acceptance of injection site reactions (ISRs), Bother from ISRs, Leg movement and Sleep categories. Domain scores were calculated as a mean of all items with the domain. The PIN response options range from 1 (totally acceptable) to 5 (not at all acceptable). This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: From Month 2/1 up to Month 12
Change From Month 2/1 in Individual Item Scores Using PIN Questionnaire- Q2M
The PIN questionnaire was used to explore the individual item scores based on anxiety before, pain, satisfaction, anxiety after and willingness categories. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is very dissatisfied and 5 was very satisfied. This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
Time frame: From Month 2/1 up to Month 12
The study consists in 2 periods: Maintenance Period and Extension Period. Any participants who successfully completed 12 months of CAB+RPV treatment in the Maintenance Phase had the option to enter the Extension Phase and continued to have access to CAB + RPV.
| Milestone | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Switch Q2M Group |
|---|---|---|---|---|
| Started | 175 | 279 | 227 | 0 |
| Completed | 152 | 255 | 213 | 0 |
| Not completed | 23 | 24 | 14 | 0 |
| Withdrew: Adverse event | 10 | 3 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 8 | 9 | 0 |
| Withdrew: Protocol deviation | 2 | 6 | 1 | 0 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 | 1 | 0 | 0 |
| Milestone | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Switch Q2M Group |
|---|---|---|---|---|
| Started | 173 | 274 | 0 | 0 |
| Completed | 150 | 247 | 0 | 0 |
| Not completed | 23 | 27 | 0 | 0 |
| Withdrew: Adverse event | 10 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 5 | 0 | 0 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 12 | 0 | 0 |
| Milestone | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Switch Q2M Group |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 143 |
| Completed | 0 | 0 | 0 | 130 |
| Not completed | 0 | 0 | 0 | 13 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 |
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population | 1.3 (0.5 to 2.9) | 0.4 (0.0 to 2.4) |
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population | 1.1 (0.4 to 2.6) | 0.4 (0.0 to 2.5) |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population | 89.4 (86.6 to 92.3) | 93.0 (89.6 to 96.3) |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population | 90.2 (87.4 to 92.9) | 92.8 (89.4 to 96.2) |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population | 92.7 (90.3 to 95.1) | 97.8 (95.9 to 99.7) |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population | 93.5 (91.2 to 95.8) | 97.8 (95.8 to 99.7) |
Protocol-defined confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>= 200 c/mL (Day 1 values are not applicable) after prior suppression to \<200 c/mL. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at Month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Cumulative number of participants with protocol defined CVF through Month 6/5 and 12/11 has been presented.
| Participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Month 6/5 | 1 | 0 |
| Month 12/11 | 2 | 0 |
Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 6 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/5 | 0.4 (0.1 to 1.6) | 0 (0.0 to 1.6) |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| log10 copies per milliliter(c/mL) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 1.5993 ± 0.10559 | 1.5947 ± 0.06640 |
| Month 6/5 | 1.6002 ± 0.09268 | 1.5910 ± 0.01182 |
| Month 12/11 | 1.6019 ± 0.13064 | 1.5911 ± 0.01552 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Logarithm to base 10 values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| log10 c/mL | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 1.5993 ± 0.10559 | 1.5947 ± 0.06640 |
| Month 6/5 | 0.0015 ± 0.13997 | -0.0039 ± 0.06826 |
| Month 12/11 | 0.0029 ± 0.17038 | -0.0041 ± 0.07172 |
Blood samples were collected and CD4+ cell count was assessed using flow cytometry. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| cells per cubic millimeter(cells/mm^3) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 670.9 ± 282.11 | 679.4 ± 306.89 |
| Month 6/5 | 689.1 ± 284.89 | 673.7 ± 290.46 |
| Month 12/11 | 711.9 ± 297.13 | 717.3 ± 317.82 |
Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| cells/mm^3 | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 670.9 ± 282.11 | 679.4 ± 306.89 |
| Month 6/5 | 20.4 ± 202.38 | -3.1 ± 197.62 |
| Month 12/11 | 35.2 ± 219.79 | 32.2 ± 208.29 |
Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.
| Participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| NNRTI | 2 | 0 |
| IN | 2 | 0 |
Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.
| Participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| NNRTI | 1 | 0 |
| IN | 1 | 0 |
Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.
| Participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| M230L | 1 | 0 |
| Q148R | 1 | 0 |
| K101E | 1 | 0 |
| G118R | 1 | 0 |
Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.
| Participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| M230L | 1 | 0 |
| Q148R | 1 | 0 |
Serum samples were collected to evaluate bone specific biomarkers: specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| micrograms per liter (ug/L) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Serum Bone Specific Alkaline Phosphatase, Baseline (Day 1) | 12.7 ± 4.27 | 12.9 ± 4.60 |
| Serum Bone Specific Alkaline Phosphatase, Month 6/5 | 0.3 ± 9.89 | 0.2 ± 2.60 |
| Serum Bone Specific Alkaline Phosphatase, Month 12/11 | 0.1 ± 5.03 | 0.5 ± 3.55 |
| Serum Osteocalcin, Baseline (Day 1) | 21.0 ± 7.35 | 20.4 ± 7.48 |
| Serum Osteocalcin, Month 6/5 | 0.4 ± 5.53 | -0.4 ± 5.11 |
| Serum Osteocalcin, Month 12/11 | 0.9 ± 6.11 | -0.6 ± 5.51 |
| Serum Procollagen 1 N-Terminal Propeptide, Baseline (Day 1) | 59.1 ± 23.06 | 59.2 ± 23.88 |
| Serum Procollagen 1 N-Terminal Propeptide, Month 6/5 | -1.5 ± 15.70 | 0.1 ± 18.53 |
| Serum Procollagen 1 N-Terminal Propeptide, Month 12/11 | -0.7 ± 19.73 | 0.6 ± 19.63 |
| Serum Type I Collagen C-Telopeptides, Baseline (Day 1) | 0.4 ± 0.25 | 0.5 ± 0.25 |
| Serum Type I Collagen C-Telopeptides, Month 6/5 | -0.1 ± 0.23 | -0.1 ± 0.21 |
| Serum Type I Collagen C-Telopeptides, Month 12/11 | 0.0 ± 0.25 | 0.0 ± 0.22 |
Serum samples were collected to evaluate bone specific biomarkers: serum 25-hydroxyvitamin D. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| nanomoles per liter (nmol/L) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 61.0 ± 34.69 | 59.9 ± 33.30 |
| Month 6/5 | 2.8 ± 29.24 | 6.0 ± 34.16 |
| Month 12/11 | -2.3 ± 29.00 | -3.1 ± 26.38 |
Serum samples were collected to evaluate renal specific biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| milligrams per liter (mg/L) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Serum beta-2 microglobulin, Baseline (Day 1) | 1.8 ± 0.40 | 1.8 ± 0.38 |
| Serum beta-2 microglobulin, Month 6/5 | 0.0 ± 0.28 | 0.0 ± 0.28 |
| Serum beta-2 microglobulin, Month 12/11 | 0.0 ± 0.33 | 0.0 ± 0.32 |
| Serum cystatin C, Baseline (Day 1) | 0.9 ± 0.13 | 0.9 ± 0.14 |
| Serum cystatin C, Month 6/5 | 0.0 ± 0.08 | 0.0 ± 0.08 |
| Serum cystatin C, Month 12/11 | 0.0 ± 0.08 | 0.0 ± 0.08 |
| Serum retinol binding protein, Baseline (Day 1) | 51.3 ± 13.01 | 52.2 ± 12.61 |
| Serum retinol binding protein, Month 6/5 | -1.0 ± 9.00 | -0.3 ± 8.75 |
| Serum retinol binding protein, Month 12/11 | -1.2 ± 9.24 | 0.2 ± 9.06 |
| Urine beta-2 microglobulin, Baseline (Day 1) | 0.2 ± 0.34 | 0.2 ± 0.40 |
| Urine beta-2 microglobulin, Month 6/5 | 0.0 ± 0.40 | 0.1 ± 0.65 |
| Urine beta-2 microglobulin, Month 12/11 | 0.0 ± 0.24 | 0.1 ± 0.52 |
Serum samples were collected to evaluate renal specific biomarkers: urine phosphate. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| millimoles per liter (mmol/L) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 20.0 ± 14.03 | 18.4 ± 13.10 |
| Month 6/5 | -1.0 ± 16.29 | 0.4 ± 15.60 |
| Month 12/11 | 0.1 ± 16.17 | -0.6 ± 15.16 |
Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein 4. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| microgram per liter (ug/L) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 114.2 ± 111.45 | 100.0 ± 82.00 |
| Month 6/5 | 0.8 ± 139.88 | 5.7 ± 105.08 |
| Month 12/11 | -0.6 ± 123.52 | -1.2 ± 105.26 |
Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein/creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| milligram per mole (mg/mol) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 8.6 ± 6.32 | 8.0 ± 5.75 |
| Month 6/5 | 0.8 ± 6.00 | -0.8 ± 7.23 |
| Month 12/11 | -0.5 ± 6.41 | 0.0 ± 4.15 |
Serum samples were collected to evaluate renal specific biomarkers: urine beta-2 microglobulin/ creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| grams per mole (g/mol) | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 0.0 ± 0.03 | 0.0 ± 0.04 |
| Month 6/5 | 0.0 ± 0.03 | 0.0 ± 0.19 |
| Month 12/11 | 0.0 ± 0.02 | 0.0 ± 0.04 |
Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Yes (Baseline) to Yes (Month 12/11) | 9 | 9 |
| Yes (Baseline) to No (Month 12/11) | 5 | 7 |
| Yes (Baseline) to Missing (Month 12/11) | 2 | 1 |
| No (Baseline) to Yes (Month 12/11) | 6 | 8 |
| No (Baseline) to No (Month 12/11) | 69 | 70 |
| No (Baseline) to Missing ((Month 12/11)) | 8 | 6 |
Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit.
| Percentage of participants | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Yes (Baseline) to Yes (Month 6/5) | 9 | 11 |
| Yes (Baseline) to No (Month 6/5) | 7 | 6 |
| Yes (Baseline) to Missing (Month 6/5) | 1 | 0 |
| No (Baseline) to Yes (Month 6/5) | 5 | 10 |
| No (Baseline) to No (Month 6/5) | 74 | 71 |
| No (Baseline) to Missing (Month 6/5) | 5 | 2 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. HOMA-IR is calculated as fasting insulin microunits per liter (microU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. Higher HOMA-IR values indicate increased insulin resistance; values \<2 is generally regarded as normal. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| HOMA-IR score | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 2.8 ± 4.05 | 3.1 ± 5.06 |
| Month 6/5 | 0.3 ± 4.11 | -0.1 ± 5.09 |
| Month 12/11 | 0.2 ± 3.99 | -0.4 ± 3.76 |
Participants who had switched from the daily oral BIK regimen to CAB + RPV, were assessed as per the preference questionnaire every two months. There were 3 preference questions included to assess the preferred treatment 1) Long-acting injectable HIV medication, 2) Daily oral HIV medication, 3) No Preference. This endpoint was only planned to be analyzed for Q2M arm only. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Data represented included maintenance withdrawal or Month 12/11.
| Percentage of participants | Oral lead-in Phase (OLI) | Direct to Injections (D2I) |
|---|---|---|
| Long-acting injectable HIV medication | 87 | 92 |
| Daily oral HIV medication | 7 | 4 |
| No Preference | 6 | 5 |
The HIVTSQs total treatment satisfaction score comprised of 11 items based on HIVTSQ questionnaire each graded on a scale of 0 (very dissatisfied) to 6 (very satisfied) which were summed to produce a total score range of 0-66. Higher scores represent greater treatment satisfaction. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Baseline (Day 1) | 57.88 ± 7.906 | 58.38 ± 8.229 |
| Month 6/5 | 3.99 ± 9.670 | -0.66 ± 7.417 |
| Month 12/11 | 4.21 ± 9.273 | -1.93 ± 8.045 |
The individual item scores on HIVTSQs scale were rated on a scale of 6 (very satisfied, convenient, flexible, etc.) to -6 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| (Item 1=Satisfaction with current treatment), Baseline (Day 1) | 5.5 ± 0.86 | 5.6 ± 0.75 |
| (Item 1=Satisfaction with current treatment), Month 6/5 | 0.1 ± 1.10 | -0.2 ± 0.91 |
| (Item 1=Satisfaction with current treatment), Month 12/11 | 0.2 ± 1.07 | -0.3 ± 1.00 |
| (Item 2=Controlled HIV), Baseline (Day 1) | 5.8 ± 0.54 | 5.8 ± 0.45 |
| (Item 2=Controlled HIV), Month 6/5 | 0.0 ± 0.80 | -0.1 ± 0.55 |
| (Item 2=Controlled HIV), Month 12/11 | 0.0 ± 0.70 | -0.1 ± 0.69 |
| (Item 3=Satisfaction with side effects of present treatment), Baseline (Day 1) | 5.5 ± 0.91 | 5.5 ± 1.02 |
| (Item 3=Satisfaction with side effects of present treatment), Month 6/5 | -0.3 ± 1.42 | 0.0 ± 1.21 |
| (Item 3=Satisfaction with side effects of present treatment), Month 12/11 | -0.1 ± 1.38 | 0.0 ± 1.16 |
| (Item 4=Satisfaction with current treatment demands), Baseline (Day 1) | 5.2 ± 1.16 | 5.2 ± 1.21 |
| (Item 4=Satisfaction with current treatment demands), Month 6/5 | 0.4 ± 1.32 | -0.1 ± 1.28 |
| (Item 4=Satisfaction with current treatment demands), Month 12/11 | 0.3 ± 1.33 | -0.2 ± 1.35 |
| (Item 5=Treatment convenience), Baseline (Day 1) | 5.0 ± 1.24 | 5.2 ± 1.16 |
| (Item 5=Treatment convenience), Month 6/5 | 0.6 ± 1.42 | -0.1 ± 1.30 |
| (Item 5=Treatment convenience), Month 12/11 | 0.7 ± 1.43 | -0.2 ± 1.33 |
| (Item 6=Treatment flexibility), Baseline (Day 1) | 4.7 ± 1.70 | 4.9 ± 1.55 |
| (Item 6=Treatment flexibility), Month 6/5 | 0.9 ± 1.77 | 0.0 ± 1.58 |
| (Item 6=Treatment flexibility), Month 12/11 | 0.9 ± 1.74 | -0.1 ± 1.58 |
| (Item 7=Satisfaction with understanding of HIV), Baseline (Day 1) | 5.5 ± 0.80 | 5.5 ± 0.92 |
| (Item 7=Satisfaction with understanding of HIV), Month 6/5 | 0.2 ± 0.81 | 0.1 ± 0.75 |
| (Item 7=Satisfaction with understanding of HIV), Month 12/11 | 0.1 ± 0.86 | 0.1 ± 0.78 |
| (Item 8=Treatment fitting in with lifestyle), Baseline (Day 1) | 5.0 ± 1.20 | 5.1 ± 1.11 |
| (Item 8=Treatment fitting in with lifestyle), Month 6/5 | 0.7 ± 1.36 | -0.1 ± 1.26 |
| (Item 8=Treatment fitting in with lifestyle), Month 12/11 | 0.7 ± 1.31 | -0.2 ± 1.38 |
| (Item 9=Recommendation of current treatment for HIV), Baseline (Day 1) | 5.5 ± 0.86 | 5.5 ± 1.02 |
| (Item 9=Recommendation of current treatment for HIV), Month 6/5 | 0.2 ± 1.10 | 0.0 ± 1.09 |
| (Item 9=Recommendation of current treatment for HIV), Month 12/11 | 0.2 ± 1.04 | -0.1 ± 1.04 |
| (Item 10=Satisfaction with present treatment continuation), Baseline (Day 1) | 4.9 ± 1.23 | 4.9 ± 1.28 |
| (Item 10=Satisfaction with present treatment continuation), Month 6/5 | 0.8 ± 1.54 | 0.0 ± 1.38 |
| (Item 10=Satisfaction with present treatment continuation), Month 12/11 | 0.9 ± 1.49 | -0.2 ± 1.45 |
| (Item 11=Ease or difficulty with current treatment), Baseline (Day 1) | 5.2 ± 1.10 | 5.3 ± 1.06 |
| (Item 11=Ease or difficulty with current treatment), Month 6/5 | 0.5 ± 1.34 | -0.2 ± 1.20 |
| (Item 11=Ease or difficulty with current treatment), Month 12/11 | 0.5 ± 1.34 | -0.3 ± 1.13 |
| (Item 12=Satisfaction with amount of discomfort/pain with current treatment), Baseline (Day 1) | 5.5 ± 1.02 | 5.6 ± 0.94 |
| (Item 12=Satisfaction with amount of discomfort/pain with current treatment), Month 6/5 | -0.6 ± 1.64 | -0.1 ± 0.93 |
| (Item 12=Satisfaction with amount of discomfort/pain with current treatment), Month 12/11 | -0.5 ± 1.54 | -0.2 ± 1.09 |
HIV treatment satisfaction change questionnaire (HIVTSQc) total Score is computed with items 1-11 which were summed to produce a total score range of -33 to 33. Higher score indicated greater improvement in the satisfaction with the treatment and lower score indicated greater deterioration in treatment satisfaction. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/11 | 26.97 ± 10.135 | 16.89 ± 14.299 |
Individual item scores were rated on a scale of +3 (much more satisfied', 'much more convenient', 'much more flexible') to -3 (much less satisfied', 'much less convenient', 'much less flexible'). Higher score indicates greater improvement, and lower score indicates greater deterioration in satisfaction with each aspect of treatment. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Q2M (OLI + D2I) | Biktarvy (BIK) |
|---|---|---|
| Item 1=Satisfaction with current treatment | 2.56 ± 1.043 | 1.60 ± 1.417 |
| Item 2=Controlled HIV | 2.47 ± 1.086 | 1.88 ± 1.375 |
| Item 3=Satisfaction with side effects of present treatment | 2.10 ± 1.388 | 1.63 ± 1.463 |
| Item 4=Satisfaction with current treatment demands | 2.41 ± 1.109 | 1.42 ± 1.560 |
| Item 5=Treatment convenience | 2.50 ± 1.070 | 1.38 ± 1.520 |
| Item 6=Treatment flexibility | 2.41 ± 1.138 | 1.24 ± 1.591 |
| Item 7=Satisfaction with understanding of HIV | 2.35 ± 1.065 | 1.94 ± 1.297 |
| Item 8=Treatment fitting in with lifestyle | 2.56 ± 0.994 | 1.43 ± 1.489 |
| Item 9=Recommendation of current treatment for HIV | 2.61 ± 1.065 | 1.73 ± 1.467 |
| Item 10=Satisfaction with present treatment continuation | 2.58 ± 1.093 | 1.22 ± 1.602 |
| Item 11=Ease or difficulty with current treatment | 2.46 ± 1.107 | 1.43 ± 1.542 |
| Item 12=Satisfaction with amount of discomfort/pain with current treatment | 1.85 ± 1.530 | 1.64 ± 1.465 |
The PIN questionnaire was used to explore the dimension scores based on 4 dimensions including acceptance of injection site reactions (ISRs), Bother from ISRs, Leg movement and Sleep categories. Domain scores were calculated as a mean of all items with the domain. The PIN response options range from 1 (totally acceptable) to 5 (not at all acceptable). This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Oral lead-in Phase (OLI) | Direct to Injections (D2I) |
|---|---|---|
| Bother of ISRs, Month 2/1 | 1.58 ± 0.568 | 1.60 ± 0.583 |
| Bother of ISRs, Month 6/5 | 0.01 ± 0.528 | -0.03 ± 0.590 |
| Bother of ISRs, Month 12/11 | 0.08 ± 0.594 | -0.04 ± 0.583 |
| Leg Movement, Month 2/1 | 1.93 ± 1.013 | 1.83 ± 0.913 |
| Leg Movement, Month 6/5 | -0.14 ± 0.779 | -0.22 ± 0.868 |
| Leg Movement, Month 12/11 | -0.18 ± 0.859 | -0.24 ± 0.817 |
| Sleep, Month 2/1 | 1.83 ± 0.936 | 1.87 ± 0.965 |
| Sleep, Month 6/5 | -0.01 ± 0.915 | -0.16 ± 0.869 |
| Sleep, Month 12/11 | -0.07 ± 0.948 | -0.17 ± 0.870 |
| Acceptance, Month 2/1 | 2.02 ± 1.017 | 2.05 ± 0.949 |
| Acceptance, Month 6/5 | -0.14 ± 0.906 | -0.13 ± 0.879 |
| Acceptance, Month 12/11 | -0.20 ± 0.873 | -0.26 ± 0.856 |
The PIN questionnaire was used to explore the individual item scores based on anxiety before, pain, satisfaction, anxiety after and willingness categories. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is very dissatisfied and 5 was very satisfied. This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.
| Scores on scale | Oral lead-in Phase (OLI) | Direct to Injections (D2I) |
|---|---|---|
| Anxiety Before, Month 2/1 | 1.9 ± 1.02 | 1.9 ± 1.02 |
| Anxiety Before, Month 6/5 | -0.14 ± 1.021 | -0.22 ± 1.000 |
| Anxiety Before, Month 12/11 | -0.28 ± 0.973 | -0.22 ± 0.914 |
| Pain, Month 2/1 | 1.8 ± 0.88 | 2.0 ± 0.93 |
| Pain, Month 6/5 | 0.09 ± 0.907 | -0.03 ± 0.935 |
| Pain, Month 12/11 | 0.13 ± 0.995 | 0.02 ± 0.943 |
| Satisfaction, Month 2/1 | 1.7 ± 0.90 | 1.6 ± 0.81 |
| Satisfaction, Month 6/5 | -0.06 ± 0.837 | 0.00 ± 0.867 |
| Satisfaction, Month 12/11 | -0.12 ± 0.861 | -0.11 ± 0.830 |
| Anxiety After, Month 2/1 | 1.8 ± 1.12 | 1.7 ± 0.96 |
| Anxiety After, Month 6/5 | -0.14 ± 0.994 | -0.04 ± 0.916 |
| Anxiety After, Month 12/11 | -0.24 ± 0.947 | -0.16 ± 0.850 |
| Willingness, Month 2/1 | 1.4 ± 0.76 | 1.4 ± 0.78 |
| Willingness, Month 6/5 | 0.01 ± 0.716 | -0.08 ± 0.794 |
| Willingness, Month 12/11 | -0.01 ± 0.744 | -0.10 ± 0.742 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to end of Extension Phase (approximately Month 27).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral lead-in Phase (OLI) | 0/175 (0%) | 11/175 (6.3%) | 156/175 (89.1%) |
| Direct to Injections (D2I) | 0/279 (0%) | 10/279 (3.6%) | 257/279 (92.1%) |
| Biktarvy (BIK) | 1/227 (0.4%) | 15/227 (6.6%) | 77/227 (33.9%) |
| Switch Q2M Group | 1/145 (0.7%) | 5/145 (3.4%) | 76/145 (52.4%) |
| Event | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Switch Q2M Group |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 2/175 | 1/279 | 0/227 | 0/145 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/175 | 1/279 | 2/227 | 0/145 |
| AppendicitisInfections and infestations | 0/175 | 0/279 | 1/227 | 1/145 |
| PyelonephritisInfections and infestations | 0/175 | 1/279 | 0/227 | 1/145 |
| Cytomegalovirus infectionInfections and infestations | 0/175 | 0/279 | 0/227 | 1/145 |
| Hepatitis CInfections and infestations | 0/175 | 0/279 | 0/227 | 1/145 |
| Sudden deathGeneral disorders | 0/175 | 0/279 | 0/227 | 1/145 |
| Hepatitis acuteHepatobiliary disorders | 0/175 | 0/279 | 0/227 | 1/145 |
| Herpes simplex meningitisInfections and infestations | 1/175 | 0/279 | 0/227 | 0/145 |
| Herpes simplex meningoencephalitisInfections and infestations | 1/175 | 0/279 | 0/227 | 0/145 |
| Event | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Switch Q2M Group |
|---|---|---|---|---|
| Injection site painGeneral disorders | 106/175 | 182/279 | 1/227 | 55/145 |
| COVID-19Infections and infestations | 34/175 | 50/279 | 38/227 | 21/145 |
| HeadacheNervous system disorders | 17/175 | 35/279 | 12/227 | 0/145 |
| Injection site indurationGeneral disorders | 20/175 | 17/279 | 0/227 | 0/145 |
| Injection site noduleGeneral disorders | 17/175 | 26/279 | 0/227 | 0/145 |
| Injection site discomfortGeneral disorders | 17/175 | 26/279 | 0/227 | 0/145 |
| FatigueGeneral disorders | 17/175 | 14/279 | 6/227 | 0/145 |
| Injection site swellingGeneral disorders | 15/175 | 27/279 | 0/227 | 0/145 |
| PyrexiaGeneral disorders | 10/175 | 26/279 | 8/227 | 0/145 |
| NasopharyngitisInfections and infestations | 8/175 | 25/279 | 10/227 | 0/145 |
| Age, Continuous(YEARS) | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 11.38 | 39.0 ± 11.09 | 38.6 ± 11.41 | 38.7 ± 11.26 |
| Sex: Female, Male(Participants) | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Total |
|---|---|---|---|---|
| Female | 27 | 52 | 41 | 120 |
| Male | 148 | 227 | 186 | 561 |
| Race/Ethnicity, Customized(Participants) | Oral lead-in Phase (OLI) | Direct to Injections (D2I) | Biktarvy (BIK) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 10 | 4 | 2 | 16 |
| Asian - Central/South Asian Heritage | 0 | 3 | 0 | 3 |
| Asian - East Asian Heritage | 1 | 0 | 2 | 3 |
| Asian - Japanese Heritage | 4 | 10 | 6 | 20 |
| Asian - South East Asian Heritage | 2 | 3 | 3 | 8 |
| Black or African American | 40 | 56 | 49 | 145 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 10 | 5 | 10 | 25 |
| White - White/Caucasian/European Heritage | 104 | 194 | 149 | 447 |
| Mixed White Race | 0 | 0 | 1 | 1 |
| Multiple | 4 | 4 | 4 | 12 |
Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · viivhealthcare.com
Ran from Nov 2020 to primary completion in Jul 2022, 20 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabotegravir · Rilpivirine